Implantable device could allow doctors to test cancer drugs in patients before prescribing chemotherapy
More than 100 drugs have been approved to treat cancer, but predicting which ones will help a particular patient is an inexact science at best.
A new device developed at MIT may change that. The implantable device, about the size of the grain of rice, can carry small doses of up to 30 different drugs. After implanting it in a tumor and letting the drugs diffuse into the tissue, researchers can measure how effectively each one kills the patient’s cancer cells.
Such a device could eliminate much of the guesswork now involved in choosing cancer treatments, says Oliver Jonas, a postdoc at MIT’s Koch Institute for Integrative Cancer Research and lead author of a paper describing the device in the April 22 online edition of Science Translational Medicine.
“You can use it to test a patient for a range of available drugs, and pick the one that works best,” Jonas says.
The paper’s senior authors are Robert Langer, the David H. Koch Professor at MIT and a member of the Koch Institute, the Institute for Medical Engineering and Science, and the Department of Chemical Engineering; and Michael Cima, the David H. Koch Professor of Engineering at MIT and a member of the Koch Institute and the Department of Materials Science and Engineering.
Putting the lab in the patient
Most of the commonly used cancer drugs work by damaging DNA or otherwise interfering with cell function. Recently, scientists have also developed more targeted drugs designed to kill tumor cells that carry a specific genetic mutation. However, it is usually difficult to predict whether a particular drug will be effective in an individual patient.
In some cases, doctors extract tumor cells, grow them in a lab dish, and treat them with different drugs to see which ones are most effective. However, this process removes the cells from their natural environment, which can play an important role in how a tumor responds to drug treatment, Jonas says.
“The approach that we thought would be good to try is to essentially put the lab into the patient,” he says. “It’s safe and you can do all of your sensitivity testing in the native microenvironment.”
The device, made from a stiff, crystalline polymer, can be implanted in a patient’s tumor using a biopsy needle. After implantation, drugs seep 200 to 300 microns into the tumor, but do not overlap with each other. Any type of drug can go into the reservoir, and the researchers can formulate the drugs so that the doses that reach the cancer cells are similar to what they would receive if the drug were given by typical delivery methods such as intravenous injection.
After one day of drug exposure, the implant is removed, along with a small sample of the tumor tissue surrounding it, and the researchers analyze the drug effects by slicing up the tissue sample and staining it with antibodies that can detect markers of cell death or proliferation.
Ranking cancer drugs
To test the device, the researchers implanted it in mice that had been grafted with human prostate, breast, and melanoma tumors. These tumors are known to have varying sensitivity to different cancer drugs, and the MIT team’s results corresponded to those previously seen differences.
The researchers then tested the device with a type of breast cancer known as triple negative, which lacks the three most common breast cancer markers: estrogen receptor, progesterone receptor, and Her2. This form of cancer is particularly aggressive, and none of the drugs used against it are targeted to a specific genetic marker.
Using the device, the researchers found that triple negative tumors responded differently to five of the drugs commonly used to treat them. The most effective was paclitaxel, followed by doxorubicin, cisplatin, gemcitabine, and lapatinib. They found the same results when delivering these drugs by intravenous injection, suggesting that the device is an accurate predictor of drug sensitivity.
The Latest on: Personalized medicine
via Google News
The Latest on: Personalized medicine
- Report Describes Case of Improved Outcome in MM With Personalized Medicineon March 6, 2021 at 11:01 am
Researchers describe the case of an older patient who underwent myeloma drug sensitivity testing as part of an effort to identify the therapies most likely to produce a response in this ...
- Personalized Medicine Is The Next Big Trend For Biotech Stocks & 1 Company Could Radically Disrupt The Industry - MarketWatchon March 5, 2021 at 2:04 am
Many are calling for personalized medicine to fit that mold. And there's nothing more personal than cancer. According to the National Cancer Institute, cancer is among the leading causes of death ...
- A Genetic Method to Predict the Effects of Personalized Treatments for Sexual Dysfunction in Womenon March 4, 2021 at 8:39 am
The influential open access journal PLOS ONE published an article today on a personalized medicine approach directed at the treatment of low sexual desire and arousal in women (Daniël Höhle, et al).
- Custom Antibody Market Worth $481 Million - Increasing Demand for Personalized Medicine and Protein Therapeuticson March 4, 2021 at 4:45 am
The global custom antibody market is projected to reach USD 481 million by 2023 from USD 313 million in 2018, at a CAGR of 8.9% ...
- Music: Medicine with no side effectson March 4, 2021 at 3:15 am
Our brains naturally synchronize to the rhythm of the music we're listening to, so, to amplify the effects on a run, build a playlist that starts off slower and then increases in BPM as you job. Or, ...
- Personalized medicine: To optimize treatment for individual patients, physicians should employ experimental designson March 3, 2021 at 5:22 am
Randomized clinical trials are the undisputed gold standard for determining whether a treatment protocol is effective for a specific disease or condition.
- Lustgarten Foundation Receives $424,000 Grant Establishing the Gail V. Coleman and Kenneth M. Bruntel Organoids for Personalized Therapy Projecton March 3, 2021 at 3:28 am
Lustgarten Foundation Receives $424,000 Grant Establishing the Gail V. Bruntel Organoids for Personalized Therapy ProjectPR NewswireWOODBURY, N.
- Parkinson's Foundation Adds University of Miami Miller School of Medicine to PD GENEration Research Studyon March 2, 2021 at 5:58 am
MIAMI and NEW YORK, March 2, 2021 /PRNewswire-HISPANIC PR WIRE/ -- The Parkinson's Foundation announced the University of Miami Miller School of Medicine is a new site for PD GENEration: ...
- DHR Health and Cipherome to Pioneer Personalized Medicine Project in Patients Undergoing Percutaneous Coronary Interventionson February 28, 2021 at 8:00 pm
Can a medical tool predict the risk of certain medications based on a patient’s genetics, and, if so, could this information lead to doctors customizi ...
- How Japan Is Using The World’s Most Powerful Supercomputer To Accelerate Personalized Medicineon February 25, 2021 at 4:33 pm
In Japan, scientists are harnessing the world's most powerful supercomputer, Fugaku, to discover new customized treatments and drug therapies.
via Bing News